AU2010202742A1 — Methods for reducing the risk of an adverse dronedarone / beta-blockers interaction in a patient suffering from atrial fibrillation

USPTO Abstract

METHOD FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILLATION SANOFI-AVENTIS The invention relates to a method for managing the risk of dronedarone /beta-lockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-lockers treatment, by performing the following steps: a- initiate beta-lockers treatment at a low dose; b- performing a electrocardiogram (ECG) verification of good tolerability; c- increase of beta-lockers dose only if results in step b) are satisfying.